Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

19
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
19
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.6K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.6K
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

16
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
16
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

913
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
913

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study.

The lancet. Gastroenterology & hepatology·2026
Same author

Contemporary preoperative assessment for colorectal surgery: new insights and developments.

BMJ open gastroenterology·2026
Same author

Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.

The New England journal of medicine·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial.

Journal of Crohn's & colitis·2026
Same author

Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease.

Frontiers in cellular and infection microbiology·2026
Same journal

Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?

Expert review of gastroenterology & hepatology·2026
Same journal

Management of gastric varices: treatment options and opportunities to improve outcomes.

Expert review of gastroenterology & hepatology·2026
Same journal

Microbial ecology and hepatocellular carcinoma: should a subset be viewed as a microbiome-conditioned malignancy?

Expert review of gastroenterology & hepatology·2026
Same journal

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Expert review of gastroenterology & hepatology·2026
Same journal

Lyon Consensus 2.0: what has changed for GERD diagnosis?

Expert review of gastroenterology & hepatology·2026
Same journal

Proton pump inhibitors in children: indications and safety.

Expert review of gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.9K

Predicting outcomes in acute severe ulcerative colitis.

Nicholas T Ventham1, Rahul Kalla, Nicholas A Kennedy

  • 1Centre for Genomics and Molecular medicine, Western General Hospital, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, UK.

Expert Review of Gastroenterology & Hepatology
|December 16, 2014
PubMed
Summary
This summary is machine-generated.

Predicting treatment failure in acute severe ulcerative colitis (ASUC) is crucial. Current risk scores, while evolving with genetics, still rely on traditional clinical and biochemical markers for patient stratification.

Keywords:
acute severe colitiscolectomymortalityoutcomesulcerative colitis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.1K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Related Experiment Videos

Last Updated: Apr 19, 2026

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.9K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.1K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Area of Science:

  • Gastroenterology and Hepatology
  • Clinical Medicine
  • Genetics and Genomics

Background:

  • Corticosteroid treatment response in acute severe ulcerative colitis (ASUC) has seen minimal improvement over five decades.
  • Early identification of patients at risk is essential for timely escalation to second-line therapies or surgical intervention.
  • Traditional risk scores (e.g., Travis, Ho) utilize clinical, radiological, and biochemical data.

Purpose of the Study:

  • To review current methodologies for predicting outcomes in ASUC.
  • To explore the integration of novel data, including genetic risk alleles, into predictive models.
  • To highlight the need for advanced scoring systems for novel rescue therapies.

Main Methods:

  • Review of established risk stratification indices for ASUC.
  • Analysis of recent advancements incorporating inflammatory bowel disease genetic risk alleles.
  • Discussion of the potential of composite scores integrating multi-omic data.

Main Results:

  • Traditional risk scores remain the current best practice despite emerging genetic models.
  • Genetic prediction models show promise but have not yet replaced established indices.
  • There is a recognized need for new scoring systems to predict failure of rescue therapies like ciclosporine and infliximab.

Conclusions:

  • Predictive models for ASUC are evolving, with a trend towards integrating diverse data types.
  • Current clinical and biochemical scores are still paramount for patient management.
  • Development of robust scoring systems for novel rescue therapies is a critical future direction.